The US government has reached a deal with Johnson & Johnson worth more than $1bn to secure 100m doses of its experimental coronavirus vaccine, as countries around the world scramble to lock up supplies for mass immunisation programmes.
The deal was announced as Moderna, a biotech company developing a rival vaccine, said it had agreed to sell some doses of its inoculation for between $32 and $37, considerably more than competing drugmakers.
The Financial Times reported last week that Moderna, which is lossmaking and has received nearly $1bn from the US to develop its inoculation, had been pitching its coronavirus vaccine to potential buyers in a range of about $50 to $60 per course, which includes two doses.
您已阅读23%（716字），剩余77%（2395字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。